Executive Vice President
Institute for Clinical Pharmacodynamics
Disclosure: Institute for Clinical Pharmacodynamics, Inc. (Employee)Spero Therapeutics (Grant/Research Support)
Dr. Bhavnani is the Executive Vice President, Translational Medicine at the Institute for Clinical Pharmacodynamics in Schenectady, New York. Her areas of scientific inquiry primarily involve anti-infective translational science and antimicrobial resistance. Her interest in anti-infective translational science involves the integration of pre-clinical pharmacokinetic-pharmacodynamic data and early clinical pharmacokinetic data to identify dosage regimens that optimize the probability of positive clinical outcomes and minimize the potential of drug toxicities. Results based on these analyses have been presented to regulatory bodies to justify dose selection for clinical trials. Dr. Bhavnani has evaluated exposure-response relationships for antimicrobial agents using pre-clinical and clinical data, the results of which have been used to support decisions for dose selection and interpretive criteria for the in vitro susceptibility testing for numerous new drug applications. Dr. Bhavnani has also undertaken such analyses to support the reappraisal of interpretive criteria for in vitro susceptibility testing of existing antimicrobial agents.
Dr. Bhavnani holds many professional society memberships, including the American Society for Microbiology, the Infectious Disease Society of America, and the International Society of Anti-Infective Pharmacology. She is the author or co-author of over 250 peer-reviewed scientific publications, book chapters, or scientific abstracts and an Associate Editor for Diagnostic Microbiology and Infectious Disease. Dr. Bhavnani serves as a voting member to the United States Antimicrobial Susceptibility Test Committee. She has served on the IDWeek Program Planning Committee from 2012 to 2015 and the American Society for Microbiology-European Society of Clinical Microbiology and Infectious Diseases Program Planning Committee from 2017 to 2021.
